title: 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
abstract: We studied (1) the effects of oral contraceptive pills (OCPs) on hirsutism, hormonal and metabolic variables in 49 polycystic ovary syndrome patients without metabolic comorbidities and (2) the effect of 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) on the response to OCP treatment. Mean age was 21.9 ± 6.5 years. Patients received monophasic OCP (20 μg ethinyl estradiol plus 75 μg gestodene), 21/28 days per cycle, during 6 months; 32 patients with severe hirsutism also received spironolactone 100 mg. The frequencies of HSD17B5 genotypes were: AA = 0.49 (55.1%), AG = 0.42 (30.6%) and GG = 0.09 (14.3%). After 6 months, body mass index and waist circumference remained unchanged regardless of the presence of allele G. A slight reduction (p < 0.05) was noted in systolic blood pressure (p < 0.05) and luteinizing hormone levels, whereas a slight increase (p < 0.05) was noted in lipids. Total testosterone and hirsutism score declined, while sex hormone binding globulin increased after OCP treatment (p < 0.05). None of these changes were associated with genotype. Insulin and homeostasis model assessment remained unchanged after treatment and did not vary according to the presence of allele G. OCP seems to ameliorate androgenic symptoms without compromising metabolic parameters. The -71A/G SNP of HSD17B5 gene did not contribute to the improvements observed.
authors.affiliation: Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clínicas de Porto Alegre, Brazil.
authors.forename: Polyana S
authors.initials: PS
authors.lastname: Maier
authors.forename: Simone S
authors.initials: SS
authors.lastname: Mattiello
authors.forename: Luiza
authors.initials: L
authors.lastname: Lages
authors.forename: Poli M
authors.initials: PM
authors.lastname: Spritzer
mesh_terms: D015096:3-Hydroxysteroid Dehydrogenases / Q000235:genetics / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000074425:Aldo-Keto Reductase Family 1 Member C3; D001938:Brazil; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D056726:Genetic Association Studies; D006628:Hirsutism / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D006911:Hydroxyprostaglandin Dehydrogenases / Q000235:genetics / Q000378:metabolism; D017588:Hyperandrogenism / Q000209:etiology / Q000517:prevention & control; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009652:Norpregnenes / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D020641:Polymorphism, Single Nucleotide; D012720:Severity of Illness Index; D012738:Sex Hormone-Binding Globulin / Q000032:analysis*; D013148:Spironolactone / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood*; D055815:Young Adult
chemical_list: D003277:Contraceptives, Oral, Combined; D000451:Mineralocorticoid Receptor Antagonists; D009652:Norpregnenes; D012738:Sex Hormone-Binding Globulin; C033273:Gestodene; D013148:Spironolactone; D013739:Testosterone; D004997:Ethinyl Estradiol; D015096:3-Hydroxysteroid Dehydrogenases; D006911:Hydroxyprostaglandin Dehydrogenases; C487341:AKR1C3 protein, human; D000074425:Aldo-Keto Reductase Family 1 Member C3